Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Credit agrmnt [a]
IMPEL PHARMACEUTICALS INC (IMPL) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 SC 13D/A Oaktree Capital Group, LLC reports a 7.8% stake in IMPEL PHARMACEUTICALS INC.
10/05/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
10/04/2023 8-K Credit agreement amendment
Docs: "OAKTREE FUND ADMINISTRATION, LLC By: Oaktree Capital Management, L.P. Its: Managing Member"
08/21/2023 8-K Credit agreement amendment
08/18/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/15/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/12/2023 144 Form 144 - Report of proposed sale of securities:
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/12/2023 8-K Quarterly results
Docs: "IMPEL PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET"
05/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/17/2023 8-K Quarterly results
04/14/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/31/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/31/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
03/27/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/27/2023 10-K Annual Report for the period ended December 31, 2022
03/24/2023 8-K Quarterly results
Docs: "IMPEL PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET"
01/09/2023 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/17/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/25/2022 EFFECT Form EFFECT - Notice of Effectiveness:
05/24/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/16/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/16/2022 8-K Quarterly results
05/16/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/26/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy